What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to officially report Amgen's fourth-quarter and full-year 2023 financial results and financial condition as of December 31, 2023, by furnishing a press release containing these details.

Why does Amgen use non-GAAP financial measures?

Amgen uses non-GAAP financial measures to provide investors with a more useful and comprehensive understanding of its financial performance and prospects. These measures exclude certain items that management believes are not indicative of the company's ongoing business operations, such as acquisition-related expenses and restructuring costs, thereby facilitating better comparisons of results across different periods.

What kind of items are excluded when calculating Amgen's non-GAAP financial measures?

Amgen excludes several types of items, including acquisition-related expenses (like amortization of acquired intangibles and impairment charges), net charges from restructuring and cost-saving initiatives, and certain other items such as gains/losses on investment transactions, impacts of nonstrategic divestitures, and certain legal settlement costs. The tax effect of these adjustments is also considered.

Are the non-GAAP financial measures presented in this report legally binding or a substitute for GAAP results?

No, Amgen explicitly states that its non-GAAP financial measures are supplementary information and are not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. The press release also notes that this information is furnished, not 'filed,' for certain purposes under the Securities Exchange Act of 1934.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed an 8-K on February 6, 2024, to report its fourth-quarter and full-year 2023 financial results. The filing primarily furnished a press release announcing these results and detailing the company's financial performance. A key aspect of the report is Amgen's use of non-GAAP financial measures to provide investors with a more comprehensive understanding of its ongoing business operations and financial health. These non-GAAP measures, which exclude items like acquisition-related expenses, restructuring costs, and certain other non-operational items, are presented alongside GAAP figures to facilitate better comparisons across periods and enhance the evaluation of the company's underlying profitability and liquidity. Investors should note that Amgen's management believes these non-GAAP measures offer valuable insights by presenting a clearer view of the company's core business performance, free from the impact of significant one-time or irregular events. The report also highlights the reconciliation of these non-GAAP figures to their closest GAAP equivalents, emphasizing transparency in financial reporting. Furthermore, the company included metrics such as Free Cash Flow (FCF) and a debt leverage ratio, which are considered important indicators of liquidity and financial stability by management and are presented to aid investor analysis.

Key Highlights

1Amgen released its Q4 and full-year 2023 financial results on February 6, 2024, via an 8-K filing.
2The report furnished a press release detailing both GAAP and non-GAAP financial performance measures.
3Non-GAAP measures are provided to offer a clearer view of ongoing business operations and facilitate period-over-period comparisons.
4Key exclusions from GAAP for non-GAAP calculations include acquisition-related expenses, restructuring costs, and certain investment/divestiture impacts.
5Free Cash Flow (FCF) is presented as a key liquidity metric.
6A debt leverage ratio is also provided as a supplemental operating metric for the full year.
7The company emphasizes that non-GAAP measures are supplemental and not a substitute for GAAP reporting.

AMGEN INC 8-K Report, Financial Results (Feb 6, 2024)

Summary

Key Highlights

Frequently Asked Questions